VIRTU THERAPEUTICS is a pharmaceutical company specializing in the development of innovative strategies to combat stem cell-induced cancers, including diffuse glioblastoma (GBM) in adults and children. We are committed to bringing new therapeutic solutions to fight this particularly aggressive form of cancer.

Our portfolio includes a groundbreaking lead molecule, DV188, along with three alternatives. DV188 is a first-in-class small molecule targeting the properties of cancer stem cells, leading them to differentiate into indolent non-stem tumor cells and restoring sensitivity to conventional anticancer treatments.

Our promising preclinical results have been achieved through collaboration with the research team led by Thierry VIROLLE (INSERM) at the Institut de Biologie Valrose (Université Côte d'Azur, Nice), in collaboration with the Institut de chimie de Nice and the University Hospital of Nice. This research has been made possible through funding from SATT SUD EST and the Cancéropôle PACA.

For more information and press inquiries, please contact us.

LOGO of VIRTU THERAPEUTICS

flag EN
flag FR